Overview

This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of VGA039 following single IV or SC dose administration in healthy subjects and Von Willebrand disease patients.

Eligibility

Key Inclusion Criteria (All Subjects)

• Subjects, 18 to 60 years of age, inclusive.
• No clinically significant laboratory, ECG, or vital signs results.

        Additional Key Inclusion Criteria (for Subjects in Part 1 Only) • Body mass index of 18-32
        kg/m2
        Additional Key Inclusion Criteria (for Subjects in Part 2 Only)
          -  Subjects with VWD who are symptomatic, defined as having a history of bleeding or
             bruising.
          -  Hemoglobin level ≥ 8 g/dL and platelet count ≥ 150 × 109/L at Screening.
        Exclusion Key Criteria (All Subjects)
          -  Use of hormonal contraceptives within 56 days prior to administration of the study
             drug.
          -  Subjects with detection of FV Leiden or Prothrombin G20210A mutation, protein C or S
             deficiency, antithrombin deficiency, or antiphospholipid antibody syndrome at
             Screening.
          -  Subjects with other known pro-thrombotic disorders or abnormal findings in any prior
             laboratory thrombophilia evaluation.
          -  History of arterial or venous thrombosis, including superficial thrombophlebitis, or
             embolism.
          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular
             disease, cerebrovascular disease, peripheral vascular disease, or metabolic
             dysfunction.
        Additional Key Exclusion Criterion (Subjects in Part 1 Only)
        • Baseline FVIII activity > 150 IU/dL.
        Additional Key Exclusion Criteria (Subjects in Part 2 Only)
          -  Baseline FVIII activity > 50 IU/dL.
          -  Any acute, clinically significant bleeding event requiring surgical or procedural
             intervention within 7 days prior to receiving study drug.